FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* PATOU GARY					2. Issuer Name and Ticker or Trading Symbol Xenon Pharmaceuticals Inc. [XENE]														10% Ow		
(Last) (First) (Middle) C/O XENON PHARMACEUTICALS INC 200 - 3650 GILMORE WAY					3. Date of Earliest Transaction (Month/Day/Year) 06/14/2018												Officer (give title below)		Other (s below)		
(Street) BURNA (City)	BY A	1	V5G 4W8	8	4. If	f Ame	ndmei	nt, Date	of (Original	Filed	(Month/D	ay/Ye	ear)		Indiv ne) X	<i>'</i>				
(City)	(3		le I - No	n-Deriv	ative	e Sec	curit	ies Ad	car	uired.	Dis	posed o	of. o	r Ben	eficia	ıllv (Owned				
1. Title of Security (Instr. 3)			2. Trans Date (Month/I	2A. Deemed Execution Date,			,	3. Transaction Code (Instr. 8)		4. Securities Acquire		Acquired	ed (A) or		5. Amount of Securities Beneficially Owned Followin Reported		Form (D) o	n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership		
							Code	v	Amount		(A) or (D)	Price	Transac (Instr. 3		tion(s)			(Instr. 4)			
Common Shares			06/14	06/14/2018					M		8,230		A	\$3.7	(1) 20		,258		D		
Common Shares			06/14	4/2018					F		2,850	5	D	\$8.3	(2)	17,	17,402		D		
Common Shares																	12,500				See Note ⁽³⁾
		7	able II -									osed of onverti				y O	wned			•	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,	4. Transaction Code (Instr 8)				6. Date Exercisa Expiration Date (Month/Day/Year				7. Title and Amount of Securities Underlying Derivative Sec (Instr. 3 and 4		14)	De Se (In	Price of crivative curity str. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Da Ex	ate kercisab		xpiration ate	Title		Amount or Number of Shares						
Stock Option (Right to	\$3.7 ⁽¹⁾	06/14/2018			M			8,230		(4)	0	6/26/2018	Con	nmon	8,230		\$0.00	0		D	

Explanation of Responses:

- 1. The exercise price was converted to U.S. dollars from \$3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.
- 2. Represents the closing price of the Company's common shares in U.S. dollars on June 13, 2018, which was converted to a Canadian dollar amount for purposes of net settlement calculations.
- 3. By Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou.
- 4. The shares subject to the option fully vested on May 31, 2011.

/s/ Joanne Smartt, Attorney-infact

06/15/2018

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.